Hodgkin's lymphoma, lymphocytic-histiocytic predominance
diseaseOn this page
Also known as classic Hodgkin lymphoma, lymphocyte-rich typeHodgkin lymphoma, lymphocyte-richHodgkin's disease, lymphocyte predominance [obs]LRCHLlymphocyte rich classical Hodgkin lymphomalymphocyte rich classical Hodgkin's diseaselymphocyte rich classical Hodgkin's lymphomalymphocyte rich Hodgkin lymphomalymphocyte rich Hodgkin's diseaselymphocyte rich Hodgkin's lymphomalymphocyte-rich Classic Hodgkin lymphomalymphocyte-rich classical Hodgkin lymphomalymphocyte-rich classical Hodgkin's lymphoma
Summary
Hodgkin’s lymphoma, lymphocytic-histiocytic predominance (MONDO:0004604) is a cancer and 4 clinical trials. Top therapeutic interventions include vinblastine, bleomycin, and brentuximab vedotin. A subtype of classic Hodgkin lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
- Clinical trials: 4
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.1 | Europe | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Hodgkin’s lymphoma, lymphocytic-histiocytic predominance |
| Mondo ID | MONDO:0004604 |
| Orphanet | 98845 |
| DOID | DOID:8543 |
| ICD-11 | 352299041 |
| NCIT | C6913 |
| SNOMED CT | 118607005 |
| UMLS | C1266194 |
| MedGen | 224769 |
| GARD | 0019593 |
| MedDRA | 10020231 |
| Is cancer (heuristic) | yes |
Also known as: classic Hodgkin lymphoma, lymphocyte-rich type · Hodgkin lymphoma, lymphocyte-rich · Hodgkin’s disease, lymphocyte predominance [obs] · LRCHL · lymphocyte rich classical Hodgkin lymphoma · lymphocyte rich classical Hodgkin’s disease · lymphocyte rich classical Hodgkin’s lymphoma · lymphocyte rich Hodgkin lymphoma · lymphocyte rich Hodgkin’s disease · lymphocyte rich Hodgkin’s lymphoma · lymphocyte-rich Classic Hodgkin lymphoma · lymphocyte-rich classical Hodgkin lymphoma · lymphocyte-rich classical Hodgkin’s lymphoma
Disease family
This is a subtype of classic Hodgkin lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › classic Hodgkin lymphoma › Hodgkin’s lymphoma, lymphocytic-histiocytic predominance
Related subtypes (3): Hodgkin’s lymphoma, lymphocytic depletion, Hodgkin’s lymphoma, mixed cellularity, nodular sclerosis classical Hodgkin lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03907488 | PHASE3 | ACTIVE_NOT_RECRUITING | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma |
| NCT03712202 | PHASE2 | ACTIVE_NOT_RECRUITING | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma |
| NCT03077828 | PHASE2 | UNKNOWN | Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
| NCT03226249 | PHASE2 | UNKNOWN | PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| VINBLASTINE | 4 | 4 |
| BLEOMYCIN | 4 | 1 |
| BRENTUXIMAB VEDOTIN | 4 | 1 |
| DACARBAZINE | 4 | 1 |
| FILGRASTIM | 4 | 1 |
| FLUDEOXYGLUCOSE F 18 | 4 | 1 |
| NIVOLUMAB | 4 | 1 |
| PEGFILGRASTIM | 4 | 1 |
| CHEMBL376464 | 0 | 2 |
| CHEMBL1574179 | 0 | 1 |
| CHEMBL4788494 | 0 | 1 |